Логотип Бактоблис
Главная
Продукты
Проблемы
Врачам
FAQ

Источники

  1. Gao L., Xu T., Huang G., et al. Oral microbiomes: more and more importance in oral cavity and whole body. Protein Cell. 2018, 9: 488-500.
  2. Zarco M.F., Vess T.J., Ginsburg G.S. The oral microbiome in health and disease and the potential impact on personalized dental medicine. Oral Dis. 2012; 18, 109-20.
  3. Park H.K., Shim S.S., Kim S.Y., et al. Molecular analysis of colonized bacteria in a human newborn infant gut. J Microbiol. 2005; 43, 345-53.
  4. Wescombe P.A., Heng N.C.K., Burton J.P., et al. Something old and something new: an update on the amazing repertoire of bacteriocins produced by Streptococcus salivarius. Probiot Antimicrob Proteins. 2010; 2, 37-45.
  5. Huffnagle G.B., Dickson R.P., Lukacs N.W. The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol. 2017 Mar;10(2):299-306.
  6. West JV Acute upper airway infections. Br Med Bull. 2002;61:215-30.
  7. Di Pierro F, Risso P, Poggi E, Timitilli A, Bolloli S, Bruno M, Caneva E, Campus R, GiannattasioA. Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in not-recurrent pediatric subjects. Minerva Pediatr. 2018;70:240-5
  8. Ren W, Zhang Q, Liu X, Zheng S, Ma L, Chen F, Xu T, Xu B. Exploring the oral microflora of preschool children. J Microbiol. 2017 Jul;55(7):531-537.
  9. Favier C.F., Vaughan E.E., De Vos W.M., et al. Molecular monitoring of succession of bacterial communities in human neonates. Appl Environ Microbiol. 2002; 68, 219-26.
  10. Park H.K., Shim S.S., Kim S.Y., et al. Molecular analysis of colonized bacteria in a human newborn infant gut. J Microbiol. 2005; 43, 345-53.
  11. Wescombe P.A., Heng N.C.K., Burton J.P., et al. Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Future Microbiol. 2009; 4, 819-35.
  12. Tagg J.R, Hale J.D.F., Wescombe P.A. BLIS-producing probiotics targeting the oral cavity. Microbiol Aust. 2012; 33, 103-5.
  13. Akaji E.A., Folaranmi N., Ashiwaju O. Halitosis: a review of the literature on its prevalence, impact and control. Oral Health Prev Dent. 2014;12(4):297-304
  14. Burton J.P., Chilcott C.N., Moore C.J., et al. A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol. 2006; 100, 754-64.
  15. Ishijima S.A., Hayama K., Burton J.P., et al. Effect of Streptococcus salivarius K12 on the in vitro growth of Candida albicans and its protective effect in an oral candidiasis model. Appl Environ Microbiol. 2012; 78: 2190-9.
  16. Di Pierro et al. Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children Drug Healthc Patient Saf. 2014; 6: 15–20.
  17. Wescombe P.A., Upton M., Dierksen K.P., et al. Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl Environ Microbiol. 2006; 72, 1459-66.
  18. Gregori G. et al. Reduction of group a beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Therapeutics and Clinical Risk Management 2016:12 87–92
  19. Toscano M, De Grandi R, Pastorelli L, Vecchi M, Drago L. A consumer's guide for probiotics: 10 golden rules for a correct use. Dig Liver Dis. 2017 Nov;49(11):1177-1184.
  20. Di Pierro F., Colombo M., Giuliani M.G., et al. Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. Eur Rev Med Pharmacol Sci. 2016; 20: 4601-6.
  21. Power D.A., Burton J.P., Chilcott C.N., et al. Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis. 2008; 27: 1261-3.
  22. Horz H.P., Meinelt A., Houben B., et al. Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral Microbiol Immunol. 2007; 22, 126-30.
  23. Burton J.P., Cowley S., Simon R.R., et al. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol. 2011; 49, 2356-64.
  24. Hyink O. et al. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl. Environ. Microbiol. 73, 1107–1113 (2007)./ Хуинк O. И соавт. Саливарцин A2 и новый лантибиотик саливарцин Б кодируются в локусе 190-кб трансмиссивного мегаплазмида в штамме пробиотика для ротовой полости – слюнной стрептококк (Streptococcus salivarius) K12. Приложение журнала «Микробиология окружающей среды»73, 1107–1113 (2007).
  25. Ди Пьерро Ф. и соавт. Использование слюнного стрептококка (Streptococcus salivarius) K12 в предотвращении стрептококковых и вирусных тонзиллофарингитов у детей. Журнал «Лекарство, здравоохранение и безопасность пациентов» 2014 год; № 6: стр. 15–20.
  26. Клинические рекомендации: Дефицит витамина D. 2021 г.
×
Являетесь ли Вы специалистом здравоохранения?